CMD22 Capital Markets Day
4
Commercial execution and innovation
NASH and Alzheimer's disease
NASH and Alzheimer's disease pipeline overview
Establishing a presence in NASH and AD
NASH:
•
Address an unmet need with no
currently available treatment
options
FGF-21 NASH
Segment scope: F3-F4c
Pipeline overview
2022
2023
2024
2025
Phase 2
.
Aim for effect on resolution of
NASH and no worsening of fibrosis,
improvement in fibrosis and no
NASH
worsening in steatohepatitis
NASH - Combination with Gilead
(semaglutide 2.4 mg, FXR, ACC inhibitor)
Segment scope: F4c patients
Phase 2b
Alzheimer's disease:
•
Opportunistic opportunity to slow
clinical progression in people with
early Alzheimer's disease
Alzheimer's
disease
Semaglutide 2.4 mg NASH
Segment scope: F2-F3
Oral semaglutide 14 mg in Alzheimer's
disease
NASH: Non-alcoholic hepatitis; AD: Alzheimer's Disease; F: Fibrosis stage; F4c: compensated cirrhosis; ACC: firsocostat; FXR: Cilofexor Farnesoid X inhibtor
Phase 3
(Part 1)
Phase 3
(Part 2)
Phase 3
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation